The IMPACT Study: IMProve Pregnancy Outcome in APS with Certolizumab Therapy

The IMPACT study will evaluate the addition of certolizumab to usual treatment in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC).

* Certolizumab is not actively transported across the placenta and is FDA approved for use in rheumatoid arthritis, psoriasis and Crohn’s disease. Hundreds of patients with these conditions have used certolizumab throughout pregnancy, without evidence of fetal malformations or adverse pregnancy outcomes.

Certolizumab therapy requires a subcutaneous injection (similar to heparin), every other week, from week 8 to week 28 of pregnancy. This is the period when we believe APS causes damage to your placenta, negatively affecting your pregnancy (your health and that of your baby).

Certolizumab will be provided free of charge to patients who are found to be eligible for and agree to participate in the study

Click here to download more information.

Recent Posts

Our Mission

Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.

This site complies with the HONcode standard for trustworthy health information: verify here.

Contact

APS Foundation of America, Inc.
P. O. Box 801
LaCrosse, WI 54602-0801

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.